Atrium Therapeutics
San Diego, California, United States · Biotechnology, Health Care, Therapeutics
Atrium Therapeutics, Inc. is a newly formed independent company resulting from the separation of Avidity Biosciences' early stage precision cardiology programs. It focuses on the development of therapeutic interventions for cardiovascular diseases leveraging its innovative programs ATR 1086 and ATR 1072. Atrium aims to advance the field of cardiology by utilizing precision medicine strategies. Thi
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- 11
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Public (RNA)
- Website
- atriumtherapeutics.com
- Company page
Recent activity at Atrium Therapeutics
- : Atrium Therapeutics has successfully closed a $50 million private placement. The funding will support the company's ongoing development efforts.
- : SEC 8-K (8.01): On October 7, 2026, Atrium Therapeutics, Inc. entered into a securities purchase agreement with accredited investors (PIPE Investors) to sell an aggregate of 5,170,384 shares of its common stock. This transaction is significant as it implies a strategic financing move that allows the company to raise capital for operational activities. The offering is structured under Regulation D, which allows these capital raises to occur without registering the securities with the SEC, thus expediting the process. Although the filing specifically corrects the number of shares outstanding after this offering, the transaction itself indicates proactive steps by Atrium Therapeutics to enhance liquidity and support its business plans.
- : SEC 8-K (1.01): On October 7, 2026, Atrium Therapeutics, Inc. entered into a Securities Purchase Agreement with accredited investors to sell 5,170,384 shares of common stock at $7.93 per share and pre-funded warrants to purchase an additional 1,134,930 shares of common stock at $7.929 each. This securities offering is expected to provide the company with significant capital to support its operations. The transaction qualifies as a material definitive agreement under Item 1.01 of Form 8-K, reflecting strategic financing efforts to enhance growth potential.
- : Atrium Therapeutics Secures Funding Through Equity Offering
- : SEC 8-K (8.01): On July 14, 2026, Atrium Therapeutics, Inc. announced that the U.S. Food and Drug Administration cleared its Investigational New Drug (IND) application for ATR 1072, enabling the start of a Phase 1/2 clinical trial aimed at treating PRKAG2 syndrome. This significant development allows the company to advance its clinical research and potentially bring a new treatment option to patients. The announcement is accompanied by a press release, provided as Exhibit 99.1, reflecting the importance of this regulatory clearance in Atrium's pipeline. The event signifies a crucial step in the company's strategy to target rare genetic conditions, which may also impact future funding and partnerships.
- : SEC 8-K (5.02): On February 26, 2026, several individuals were elected as directors of the Company in connection with a Distribution. The newly elected directors include Carsten Boess, W. Michael Flanagan, Simona Skerjanec, and Troy Wilson, with respective terms expiring at future annual meetings after the Distribution's completion. Additionally, the filing details the election of Kathleen Gallagher as President and Brendan Winslow as Chief Financial Officer. The members of the Audit Committee and Human Capital Management Committee were also appointed among the new directors. Compensation arrangements for the non-employee directors are outlined in the referenced Information Statement, and no related party transactions were disclosed. This election reflects strategic shifts in the company's management around the Distribution event, suggesting future governance and operational directions.
- : SEC 8-K (1.01): On February 26, 2026, Avidity Biosciences, Inc. completed the separation of its early stage precision cardiology programs, which included ATR 1086 and ATR 1072, and certain collaboration agreements with Bristol-Myers Squibb Company and Eli Lilly and Company, into a new publicly traded company, Atrium Therapeutics, Inc. This material definitive agreement also involved the distribution of Atrium's common stock to Avidity's shareholders at a ratio of 1 to 10, providing Avidity's shareholders with shares of Atrium Therapeutics for their investment in Avidity. This strategic move is aimed at targeting a focused market on precision cardiology, potentially enhancing value for shareholders and shareholders.
- : SEC 8-K (7.01): Atrium Therapeutics, Inc. reported a Regulation FD Disclosure regarding a pro rata distribution of its common stock by Avidity Biosciences, Inc. to Avidity’s shareholders. As of February 26, 2026, a total of 15,514,966 shares of Atrium's stock were distributed at a ratio of one share for every ten shares held by Avidity's common stockholders. Following this distribution, Avidity no longer retains any equity interests in Atrium. Additionally, the anticipated closing of the acquisition of Avidity by Novartis AG is scheduled for February 27, 2026, subject to customary conditions. The shares of Atrium are set to begin trading on February 27, 2026, under the symbol 'RNA'. This event indicates significant corporate restructuring and market movements affecting both companies involved.
Atrium Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2026 | Post-IPO Equity | $50.0M |
| Oct 2026 | Post-IPO Equity | $5.2M |
Leadership
- Tejas Lahoti, Principal Scientist
- Jordan Cumsky, Talent Acquisition
Verified email and direct lines for Atrium Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Atrium Therapeutics in the news
- Atrium Therapeutics to Participate in Upcoming Investor Conferences - Investing News Network (Sep 02, 2026)
- Atrium Therapeutics Reports Second Quarter 2026 Financial Results - PR Newswire (Aug 13, 2026)
- Atrium Therapeutics Reports First Quarter 2026 Financial Results - Investing News Network (May 14, 2026)
- Atrium Therapeutics, Inc. (RNA) Company Profile & Facts - Yahoo! Finance Canada (May 17, 2020)
- Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome - PR Newswire (Jul 14, 2026)
- Atrium Therapeutics, Inc. (RNA) Company Information - Simply Wall Street (Feb 28, 2026)
- Atrium Therapeutics, Inc. (RNA) company profile and facts - Yahoo Finance Australia (Jun 18, 2018)
- Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration - PR Newswire (Aug 13, 2026)
Companies similar to Atrium Therapeutics
- Aqua Medical · Biotechnology, Health Care, Therapeutics
- Nouscom · Biotechnology, Health Care, Therapeutics
- Aitiologic · Biotechnology, Health Care, Therapeutics
- Ensho Therapeutics · Biotechnology, Health Care, Therapeutics
- Amani Therapeutics · Biotechnology, Health Care, Therapeutics
About Atrium Therapeutics: questions and answers
What does Atrium Therapeutics do?
Atrium Therapeutics, Inc. is a newly formed independent company resulting from the separation of Avidity Biosciences' early stage precision cardiology programs. It focuses on the development of therapeutic interventions for cardiovascular diseases leveraging its innovative programs ATR 1086 and ATR 1072. Atrium aims to advance the field of cardiology by utilizing precision medicine strategies. Thi
Where is Atrium Therapeutics headquartered?
Atrium Therapeutics is headquartered in San Diego, California, United States.
How many employees does Atrium Therapeutics have?
Atrium Therapeutics has about 11 employees.
Has Atrium Therapeutics raised funding?
Yes. Fundz has recorded 2 funding events for Atrium Therapeutics. The most recent, Post-IPO Equity of $50.0M, was in Oct 2026.
What is the latest news on Atrium Therapeutics?
On Oct 08, 2026, Atrium Therapeutics has successfully closed a $50 million private placement. The funding will support the company's ongoing development efforts.
Is Atrium Therapeutics a public company?
Yes. Atrium Therapeutics is publicly traded under the ticker RNA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy